Epigenetic enzyme EZH2 is overexpressed in three RCC subtype cohorts and EZH2 inhibition by small‐molecule tazemetostat induces antitumorigenic effects in RCC cells. The gene discussed is EZH2; the disease is renal cell carcinoma.